Total thrombus formation of patients with NSTEMI treated with clopidogrel in the presence or absence of VLD rivaroxaban. (A) Representative tracings and (B) arithmetic means ± SEM (n = 14) of occlusion start time (T10), AUC, and OT of total thrombus formation on a collagen- and tissue factor-coated (AR) chip in recalcified citrated whole blood from patients with NSTEMI before (baseline) and after medication with clopidogrel + ASA at d1 in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro), as well as after medication with clopidogrel + ASA and 2.5 mg rivaroxaban twice daily at d2 (in vivo). *P < .05, **P < .01, and ***P < .001 indicate statistically significant differences from solvent control at the indicated time point. #P < .05 and ##P < .01 indicate significant differences from baseline.
